Browsing Tag
California
569 posts
Willdan (WLDN) completes $285m Mantis acquisition, but can new earnings offset debt costs?
Willdan Group has completed its $285 million acquisition of Mantis Innovation, adding an energy management business expected to generate $120 million in annual net revenue. The purchase expands its commercial and industrial capabilities, but the financing structure and anticipated 2027 earnings contribution will determine whether the deal improves shareholder returns.
Pregnant woman killed, six wounded in California Spirit Halloween store shooting
A 31-year-old pregnant woman was killed and six men were wounded in a shooting at a Spirit Halloween store in Fairfield, California, on October 30. Police believe the incident involved a single attacker and was targeted, but they have not announced a motive or made an arrest.
Aspen Neuroscience (ASPE) prices $140.6m IPO at $15 as Parkinson’s therapy enters pivotal development phase
Aspen Neuroscience has priced its Nasdaq initial public offering at $15 per share, the bottom of its proposed range, as it prepares to advance the investigational Parkinson's disease cell therapy sasineprocel into Phase 3 testing. The financing extends the company's expected operating runway into the second half of 2028, but its clinical programme remains expensive, and the company expects to require additional capital before development is complete.
US judge blocks Trump administration from threatening election workers before midterms
A federal judge has temporarily barred the Trump administration from threatening election officials with prosecution or pressuring them to change ballot procedures based on disputed voter-eligibility claims. The nationwide order, issued on October 30, will remain in effect through November 16 unless modified by the court.
California ballot ruling: Appeals court rejects Trump administration’s 20,000-voter bid
A federal appeals court has rejected an emergency Trump administration attempt to separate approximately 20,000 California mail ballots associated with disputed citizenship records. The October 30 ruling leaves established state election procedures in place ahead of the November 3 midterm elections but does not finally resolve the underlying lawsuit.
Oak Hill Capital to acquire majority stake in Wyyerd from Carlyle
Oak Hill Capital has agreed to acquire majority ownership of Wyyerd Group Holdings from Carlyle following five years of significant network expansion. The deal brings a regional broadband platform into an investment portfolio spanning 37 US states, but its financial returns will depend on subscriber growth, construction economics and capital deployment.
Fortinet (NASDAQ: FTNT) plunges 21%. Is recurring revenue the problem?
Fortinet reported 29% billings growth, stronger earnings and record third-quarter operating margins, yet its shares suffered a dramatic selloff. A reduced services forecast, delayed subscription activations and slowing firewall hardware growth explain why investors are questioning the durability of its expansion.
Enphase (NASDAQ: ENPH) has $1.08bn in solar agreements. Why the 16% fall?
Enphase Energy has signed more than US$1 billion of tax-credit-related product arrangements, yet its shares plunged after another disappointing earnings report. Weak residential solar demand, falling margins and the lengthy commercialisation timetable for its AI power technology raise an important question about when growth can recover.
Glaukos (NYSE: GKOS) targets $1bn in sales. Can Epioxa offset iDose risk?
Glaukos shares surged in after-hours trading after the company raised its 2026 revenue forecast and introduced a US$1 billion sales target for 2027. But the ambitious outlook depends on a successful Epioxa rollout and continued demand for iDose TR, whose Medicare coverage remains under review.
Octant’s OCT-980 gains FDA orphan status, but can an oral molecule slow inherited vision loss?
Octant has received FDA orphan drug designation for OCT-980, an investigational oral therapy targeting protein misfolding associated with inherited retinal degeneration. The regulatory milestone follows the first patient dosing in September and supports development of a potentially disease-modifying treatment for rhodopsin-associated autosomal dominant retinitis pigmentosa.